

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/68		A1	(11) International Publication Number: WO 91/00925 (43) International Publication Date: 24 January 1991 (24.01.91)
(21) International Application Number: PCT/US90/03932 (22) International Filing Date: 13 July 1990 (13.07.90) (30) Priority data: 379,087 13 July 1989 (13.07.89) US (71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). (72) Inventors: THILLY, William, G. ; 12 Brooks Street, Winchester, MA 01890 (US). KEOHAVONG, Phouthone ; 12 Cottage Street, Cambridge, MA 02139 (US). (74) Agents: GRANAHAH, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).			(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published With international search report.

(54) Title: DETERMINATION OF A MUTATIONAL SPECTRUM

(57) Abstract

A method of resolving (physically separating) mutant DNA from nonmutant DNA and a method of defining or establishing a mutational spectrum or profile of alterations present in nucleic acid sequences from a sample to be analyzed, such as a tissue or body fluid. The present method is based on the fact that it is possible, through the use of DGGE, to separate nucleic acid sequences which differ by only a single base change and on the ability to detect the separate mutant molecules. The present invention, in another aspect, relates to a method for determining a mutational spectrum in a DNA sequence of interest present in a population of cells. The method of the present invention is useful as a diagnostic or analytical tool in forensic science in assessing environmental and/or occupational exposures to potentially genetically toxic materials (also referred to as potential mutagens); in biotechnology, particularly in the study of the relationship between the amino acid sequence of enzymes and other biologically-active proteins or protein-containing substances and their respective functions; and in determining the effects of drugs, cosmetics and other chemicals for which toxicity data must be obtained.



DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CM	Cameroon	LI	Liechtenstein	SU	Soviet Union
DE	Germany	LK	Sri Lanka	TD	Chad
DK	Denmark	LU	Luxembourg	TG	Togo
				US	United States of America

-1-

DETERMINATION OF A MUTATIONAL SPECTRUMDescriptionBackground of the Invention

05 Several methods are currently available which
can be used to study point mutations in a DNA
molecule. For example, it is possible to isolate a
variant cell recognized by a DNA sequence of
interest, such as one thought to contain a mutation,
and then sequence the cloned product, using known
10 techniques. Alternatively, DNA to be analyzed, such
as tumor DNA, can be cloned, amplified and
sequenced, also using known techniques. Although it
is possible, using presently-available method, to
study individual DNA mutations and to determine a
15 mutational spectrum or profile or alterations in a
selected DNA sequence, to do so is time-consuming
and tedious. This is due at least in part to the
fact that a large number of mutants, each of which
must be isolated one at a time, must be analyzed in
20 order to get a statistically reproducible spectrum.
For example, it is reasonable to assume that
approximately 10 mutants per base pair (bp) of DNA
sequence is necessary to give a statistically
reproducible result. Thus, in the case in which the
25 mutational spectrum of a 100 bp DNA sequence is to
be determined, approximately 1000 mutants must be

-2-

assessed. Using presently-available methods, each assessment requires considerable time (e.g., 1 day per mutant analyzed) and, thus, carrying out the 1000 assessments needed for a 100 bp DNA sequence is
05 work-intensive.

In addition, presently-available methods are limited to cases in which a particular mutation is present in the germ cell of an individual or other cases in which the frequency of a particular
10 mutation is relatively high (e.g., exceeding 0.1%). A method which would facilitate the detection of point mutations occurring at much lower frequencies, such as occur in nature, would be extremely
15 valuable, particularly in situations such as those in which exposure to a toxic substance results in a useful diagnostic set of alterations or single base changes in genetic material.

Summary of the Invention

The present invention pertains to a method of
20 resolving (i.e., physically separating) mutant DNA of known sequence from nonmutant DNA and of determining or establishing a mutational spectrum, which is a profile or pattern of alterations present in DNA from a selected source, such as cells from a
25 selected organ or a blood sample. In particular, the present method is useful for separating and identifying selected mutant DNA sequences from a complex mixed DNA population which contains the selected or target mutant DNA sequence(s), mutant
30 DNA sequences other than the selected mutant DNA sequences and non-mutant DNA sequences. The method

- 3 -

(i.e., is able to resolve mutants present at a much lower frequency) than previously-available methods. Using the method of the present invention, 100 mutant nucleotide sequences among 100,000,000 nonmutant nucleotide sequences have been resolved and, based on subsequent observations in human cell experiments, it appears to have a resolving power of at least 100 times greater (i.e., 100 mutant DNA sequences in 10,000,000,000 nonmutant DNA sequences). The subject method makes it possible to resolve DNA in those contexts in which the mutational frequency is approximately 1 to 1×10^{-8} and approximately 100 copies of selected mutant DNA sequence, referred to as a target DNA sequence, occur in the sample being analyzed.

As a result, it is possible to resolve mutant DNA sequences and establish mutational spectra in a cell population drawn directly from human or other animal tissue. In the method of the present invention, mutant DNA sequences are those which differ by one or more nucleotides from the corresponding naturally- occurring, unaltered DNA sequence. These differences include nucleotide modifications, deletions, substitutions or insertions. The present invention further pertains to a method of identifying one or more mutations (i.e., alterations or changes from the corresponding naturally- occurring) which confer a selective advantage or disadvantage on cells in which the mutations(s) is present.

DNA to be analyzed is isolated from cells in which it occurs, is processed, if needed, in such a

-4-

endonucleases or other agent capable of cutting the DNA in a sequence-specific manner and cut with one or more appropriately-selected restriction endonucleases or other sequence-specific agent to produce DNA fragments. Optionally, the resulting mixture of fragments of varying sizes can be separated or fractionated on the basis of molecular weight, using known techniques, and fragments of appropriate predetermined size are selected. The resulting digestion products or fragments are boiled and cooled under controlled conditions to allow nonmutant molecules and mutant molecules to form heteroduplexes. The mixture of fragments (or the fragments selected on the basis of size if the optional separation step is carried out) is separated into heteroduplexes and homoduplexes by means of denaturing gradient gel electrophoresis, (DGGE), which results in an initial separation of most (e.g., 99% or more) of the nonmutant (wild type or normal) DNA in the total DNA from the mutant DNA). The heteroduplexes obtained, which include mutant-containing and nonmutant complexes, are used for further assessment according to the present method and determination of the mutational spectrum. The profile or pattern of mutations in heteroduplexes which are mutant-containing can be established by making the mutations "visible" (detectable) by means of high fidelity, DNA amplification followed by a second separation of heteroduplexes from homoduplexes using DGGE and sequence determination; use of appropriately-labeled probes (e.g., fluorophore-labeled or isotopically-

- 5 -

labeled wild type DNA) and a detection means capable of detecting and recording the label used; or other known techniques.

05 In another aspect, the present invention is a method of defining or establishing a mutational spectrum in a DNA sequence of interest present in a population of cells. A mutation to be detected can occur with a frequency as low as 1×10^{-8} , given that at least 10^{10} copies of the DNA sequence of interest
10 (i.e., a DNA sequence which includes the mutation(s) to be detected, if such mutation(s) are present). This means that it is possible to observe mutational spectra in a cell population obtained directly from human or other animal tissue or body fluids. In
15 defining the mutational spectrum, DNA from the cells of interest is processed, mutations present in the DNA sequence of interest are identified and characterized, as described above, and the characteristics of the sample DNA (suspected of containing
20 one or more alterations or differences from the naturally-occurring sequence) are compared with those of wild-type or unaltered DNA. The resulting pattern of differences in sequence (pattern of mutations), which may include one or many differences,
25 is the mutational spectrum. After sufficient analysis and verification in a sufficient number of samples from the same individual, a particular pattern of mutations can be shown to be indicative of such an exposure and used as an
30 analytical or diagnostic tool. As part of this process, normal DNA from an individual whose DNA (e.g., from a specific affected tissue or organ or

-6-

serve as a standard against which the sequence of DNA from the abnormal or affected site can be compared in determining whether mutations exist and establishing a mutational spectrum.

05 The method of the present invention can be used to identify one or more mutations which confer a selective advantage or disadvantage upon cells in which the mutations are present.

10 The method of the present invention makes it possible to detect mutations in DNA which occur at frequencies which cannot easily be detected using presently-available techniques. The method is, therefore, particularly useful in those contexts in which minor changes or differences in nucleotide
15 sequence, such as a point mutation or limited number of altered nucleotides, are associated with or the cause of a particular event, such as exposure to a material known or thought to be toxic or the occurrence of a particular disease. The present
20 method can be used as a diagnostic tool in assessing results of occupational or environmental exposures to genetically toxic or harmful materials, as a diagnostic tool in a forensic context, as a means of carrying out pharmaceutical testing and as a tool in
25 biotechnology for determining the relationship between amino acid sequence and function of proteinaceous materials, such as enzymes.

Brief Description of the Drawings

Figure 1 is a schematic representation of the method of the present invention.

30 Figure 2 is a diagram showing (A) the melting

-7-

and (B) the positions of primers (P) used to amplify the exon 3 sequence.

Detailed Description of the Invention

05 The present invention pertains to a method of
resolving mutant nucleic acid sequences from
nonmutant nucleic acid sequences and to a method of
defining or establishing a mutational spectrum or
profile of alterations present in nucleic acid
sequences from a sample to be analyzed, such as a
10 tissue or body fluid. The present method is based
on the fact that it is possible, through the use of
DGGE, to separate nucleic acid sequences which
differ by only a single base change and on the
ability to detect the separate mutant molecules
15 either by increasing the number of copies by DNA
amplification or by means, such as a fluorescent
marker and laser excitation and fluorescence
detector, sufficiently sensitive to detect mutations
which occur at a low frequency.

20 Briefly, the present method includes the
following steps, which are represented schematically
in Figure 1. DNA to be analyzed for the presence of
a mutant sequence or mutant sequences (DNA of
interest) is obtained, using known techniques, from
25 a tissue, body fluid or other sample (e.g.,
bacterium, virus, other microorganism). The number
of cells needed for analysis is dependent on the
particular application (particular mutation(s) to be
detected) and the numbers of copies of the DNA
30 sequence of interest (i.e., the DNA sequence to be
analyzed for the presence or absence of mutation(s)

- 8 -

have at least 10 mutants present in the DNA sequences for each base pair in the DNA sequence of interest. In this way, it is possible to establish a sufficiently precise mutational spectrum, in which
05 the frequency of a mutation which occurs as 1% of the total mutants present would be estimated with a standard deviation of approximately 15%.

DNA to be analyzed can be that obtained from any type of cell in which DNA is the genetic code
10 and can be of nuclear or non-nuclear origin (e.g., from mitochondria, chloroplasts). As used herein and particularly with reference to Figure 1, the term genomic DNA refers to any DNA constituting the hereditary material in a cell and includes all DNA
15 in a cell, including that in organelles. For assessment of mutations in humans and other mammals, mitochondrial genes are the preferred DNA source because of the high copy number in each cell, which means that the tissue sample size required is
20 smaller and DNA isolation is less difficult than would be the case if another DNA source were used.

DNA to be analyzed is fragmented or digested, generally by cutting with a selected restriction endonuclease(s) or other agent which can
25 recognizably cut DNA, such as a sequence-specific chemical agent. The resulting digestion product includes fragments of varying length, only some of which include the DNA sequence in which the mutation(s) of interest, if present, occur. The
30 fragmented DNA can, optionally, be separated initially on the basis of molecular weight to remove fragments of inappropriate size. For example, the

-9-

agarose or acrylamide gel along with known molecular weight standards. The portion of the gel containing the DNA sequence of interest (and any other fragments of comparable molecular weight) can then
05 be excised from the gel by, for example, being cut out. The DNA contained within the excised gel portion can then be purified from the gel material, for example, by electro-elution into dialysis tubing followed by ethanol precipitation.

10 The desired DNA fragments, or DNA fragments of interest, are selected on the basis of known DNA sequence, as well as suitability for recognition of mutants in denaturing gradient electrophoretic gels and for amplification under conditions of high
15 fidelity, copy number and the occurrence of polymorphisms. For example, suitability for recognition in denaturing gradient electrophoretic gels is assessed by determining that a low melting domain approximately 100 to 1000 base pairs (bp) in
20 size is in close proximity to (generally, contiguous to) a higher melting domain approximately 50 bp or more in size in such a manner tht when the low melting domain of the fragment in which they occur melts on a gradient denaturing gel, the fragment has
25 characteristically reduced mobility in the polyacrylamide electrophoretic gel. The characteristically reduced mobility is used to identify fragments containing mutant DNA. Preferably, there are also appropriately located
30 restriction enzyme sites or other DNA sequences suitable for cleaving the mutation-containing segment (target DNA) from the isolated DNA fragment

-10-

As to the other criteria on which DNA fragments of interest are selected: the fragments must be suitable for high fidelity amplification because they are screened iteratively; the copy number must be sufficiently high (e.g., in genetic toxicity applications, the number of DNA sequences of interest are present at many more than 100 copies per cell); and there should be few or no genetic polymorphisms in the DNA of interest, since some inherited variation in multi copy sequences may interfere with assessment of the mutational spectrum.

The digestion product, which can be the entire mixture produced as a result of the enzymatic or chemical fragmentation of genomic DNA or a portion of the mixture selected to contain fragments of the correct size (i.e., obtained via the optional separation step), is subsequently processed to maximize formation of heteroduplex molecules. In general, this will be carried out by boiling the digestion product and allowing it to cool under controlled conditions, resulting in denaturation (separation into two strands) of the double stranded DNA and reannealing of strands to form duplexes. Nonmutant DNA forms complexes with mutant DNA, which, as a result, is uniformly present in a heteroduplex. In most contexts in which the present method is used, wild type DNA (non mutant DNA) is present in excess and heating and cooling of the digestion product can be carried out without the need for additional wild type sequences. In those instances in which this is not the case (e.g.

-11-

type homoduplexes prior to boiling and reannealing may be necessary to ensure that a molar excess ($\geq 10X$) of wild type sequences is present and, thus, reduce formation of mutant:mutant duplexes.

05 Mutant-containing heteroduplex molecules are then separated from wild-type homoduplex molecules by denaturing gradient gel electrophoresis or other process by which double-stranded DNA fragments can be separated on the basis of a small difference in
10 sequence. As the molecules migrate into the denaturing gradient, the heteroduplex molecules, which contain at least one mismatched base pair, melt at a lower denaturant concentration than that at which the wild-type homoduplex molecules melt. By the
15 time the wild-type homoduplex melts, there is a significant physical separation between it and the two mutant heteroduplex pairs, which have reasonably unique (identifiable) positions on the gel.
(Because of the presence in double-stranded DNA of a
20 Watson and a Crick strand, two heteroduplexes, which can differ in the distance they move in the gel, are formed for each mutant.)

Following separation, the portion of the gel containing the wild-type homoduplex fragments is
25 excised and discarded. The heteroduplex molecules present in the remaining gel material can be visualized (i.e., their characteristics, such as size and nucleic acid sequence, can be assessed) by one of two procedures, which are described below.

30 In one embodiment of the present method, as represented in Figure 1, Steps 7-9, the DNA present in the selected heteroduplexes is amplified and

-12-

heteroduplexes is amplified using a high fidelity DNA amplification method such as that described in co-pending U. S. patent application Serial No. 07/065,257, the teachings of which are incorporated
05 herein by reference. The high fidelity amplification product is boiled and cooled, to promote or maximize formation of heteroduplexes which contain mutant:nonmutant DNA sequences. In general, wild type (normal) DNA is present in
10 sufficient quantities; in those cases in which wild type DNA is not in excess, it is added before boiling and cooling are carried out. In either case, this results in production of a greater number of mutant-containing heteroduplexes, which are a
15 mixture of heteroduplexes (selected or target mutant DNA sequences and other mutant DNA sequences). The heteroduplexes are subjected to DGGE or other procedure capable of separating DNA fragments on the basis of a small difference in nucleic acid
20 sequence. This results in separation among mutants, which are then individually visualized using known techniques, such as use of an isotopically labeled probe and autoradiography.

The oligonucleotide primers used in the
25 amplification procedure (e.g., Steps 7 and 9) can be chemically synthesized. To facilitate the identification of mutant-containing heteroduplex bands in subsequent denaturing gradient gels, the oligonucleotide primers can be labelled with a
30 reporter group (e.g., Step 7), such as a radioactive material, using well known techniques. Such reporter groups are well known to those skilled in

-13-

05 The primer is added to the purified DNA mixture, enriched in mutant heteroduplex molecules, in a sufficient molar excess to prime DNA synthesis efficiently. The mixture is heated to denature the mutant heteroduplexes and allowed to cool slowly.

10 Any of a variety of DNA polymerases can be used in the amplification protocol. These include T4 DNA polymerase (Keohavong et al., DNA, 7:63-70 (1988)); modified and unmodified T7 DNA polymerase (Keohavong et al., Gene, 71:211-216 (1988)); the Klenow
15 fragment of DNA polymerase I (Saiki et al., Science, 230:1350-1354 (1988); Mullis et al., Methods Enzymol., 155:335-350 (1987)); and Taq DNA polymerase (Saiki et al., Science, 239:487-491
20 (1988)). Following amplification, amplified sequences in the amplification mixture include mutant homoduplex molecules, and wild type homoduplex molecules. The mixture is then heated and cooled under conditions appropriate for hetero-
25 duplex formation. As a result of the excess of wild-type hydrogen bonding partners, essentially all mutant-containing strands anneal with a wild-type strand to form heteroduplex molecules.

30 When this mixture is run on a denaturing gradient gel, a series of bands results. Homoduplex molecules migrate further in the gel and achieve greater penetration into the denaturing gradient than the bands which represent the heteroduplex molecules. For each individual mutation within the DNA sequence of interest, two labelled heteroduplex bands occur on the autoradiograph.

-14-

The reason for this is that each strand of mutant homoduplex, following denaturation and annealing, forms a unique heteroduplex molecular species. Each of the two heteroduplex species melts at a
05 characteristic temperature and the two species are resolvable by DGGE; each is a band with a characteristic location on the gel.

Individual band(s) containing the mutant DNA is/are recovered (e.g., by isolating radioactive
10 bands by cutting, electroeluting DNA from each slice and recovering the DNA from each by ethanol precipitation).

In an alternative embodiment of the present method, also represented in Figure 1, DNA in
15 mutant-containing heteroduplexes is visualized without the need for amplification. In this embodiment, a reporter or marker molecule and a device sufficiently sensitive to detect mutants present at the unamplified levels (e.g., at
20 approximately 1 mutant nucleotide sequence in 100,000,000 nonmutant nucleotide sequences) are used. For example, a fluorescent molecule can be used to label the heteroduplex molecules (e.g., by combining denatured or single stranded mutant DNA
25 with an excess of normal or wild type DNA bearing a fluorescent label, under conditions appropriate for formation of heteroduplexes). A scanning separation device in which the emitted light of the fluorophore is made specific by appropriate filters can then be
30 used to detect the fluorescently-labeled mutant-containing heteroduplexes. Alternatively, it is possible to use another charge couple device or

-15-

recording a small number of photons of specific wave number).

05 The mutant DNA to be resolved by the subject method can be obtained by known techniques from a wide variety of sample types, including a mixture of DNA produced by genetic engineering or recombinant DNA method; an animal tissue or body fluid sample; a water sample; or any other DNA-containing material.

10 In the case in which alteration(s) in a specific gene or DNA region are to be resolved, DNA obtained from a sample to be analyzed is digested with one or more restriction endonucleases whose recognition sequences flank that gene or DNA region. These recognition sequences need not be located
15 precisely at the boundaries of the gene or region.

As described in detail in the Exemplification, the present method has been used to separate mutant sequences created during polymerase-mediated amplification of the human HPRT gene exon 3 sequence
20 from the correctly amplified sequence. As described, exon 3 of the human HPRT gene was amplified using T4 DNA polymerase, modified and unmodified T7 DNA polymerases and Klenow fragment.

25 Separation of polymerase-induced mutant sequences from correctly amplified sequences was maximized by analyzing the PCR products as hetero-duplex mutant:wild-type sequences using DGGE. Each band isolated from denaturing gradient gels was amplified (using PCR) an additional 10^2 to 10^3 -fold
30 and separated by another DGGE. Results showed that the present method, in which HPRT exon 3 was amplified using modified T7 DNA polymerase, can suc-

-16-

being amplified a first time and can detect a mutant fraction of 10^{-4} after being amplified an additional 10^2 fold and separated by a second DGGE.

05 The present invention, in another aspect,
relates to a method for determining a mutational
spectrum in a DNA sequence of interest present in a
population of cells. The term "mutational spec-
trum", as used herein refers to the compilation of
10 data regarding small alterations in nucleic acid
sequence (e.g., point mutations) identified within
the DNA sequence of interest. For example, assume
that a DNA sequence of interest is 100 bp in length,
and 4 point mutations are identified within that se-
quence using the method of the subject invention.
15 Assume further that no single molecule is identified
as having more than one point mutation. The muta-
tional spectrum of the 100 base pair region com-
prises a compilation, or list, of the four mutations
which includes the position of the mutation (e.g.,
20 nucleotides 1,9,47,63), as well as the specific
nucleotide change found to occur at the particular
position (e.g. A→G; C→A; T→A; G→C, respectively).

To determine a mutational spectrum, the steps
described above for detecting resolution of a mutant
25 DNA species from a non-mutant DNA species are
carried out. Following resolution by denaturing
gradient gel electrophoresis, gel portions con-
taining labelled heteroduplex bands are excised
individually and DNA is purified from the gel
30 material. To determine an individual mutation
responsible for the heteroduplex structure, the DNA
sequence of the region of interest is determined

-17-

determined by a number of methods, such as the well known dideoxy chain termination method.

By comparing the sequence determined in this manner with the known wild-type (nonmutant) sequence, individual mutations can be characterized. The results of such analysis, when compiled, represent a determination of the mutational spectrum of the DNA sequence of interest. The nonmutant sequence to which the sequence of mutated DNA is compared can be that obtained by analysis of normal (nonmutant) DNA from the individual whose DNA is being assessed. That is, the individual can serve as his or her own reference or control. For example, the mutational spectrum of DNA in cells obtained from a tumor in the individual can be compared with nonmutant DNA from that individual. Alternatively, the information obtained from DNA from an individual, suspected of containing one or more mutations, can be compared with an "established" mutational spectrum. Such an established spectrum is the pattern or profile, previously established by assessing a sufficient number of samples from individuals known to have been exposed to the same genetically toxic substance or event, of mutations known to be associated with the exposure or event for which the individual is being assessed. For example, in the case of an individual with a particular adverse effect (e.g., a liver tumor) thought to be caused by occupational exposure to a particular chemical, the results of analysis of the individual's DNA by the present method (i.e., the individual's mutational spectrum)

-18-

shown to be associated with the exposure of interest. Alternatively, if such an established mutational spectrum is not available, the individual's mutational spectrum can be compared with the mutational spectrum of normal cells of the same type from the individual, grown in the presence of the suspected mutagen and analyzed by the present method.

The method of the present invention is useful as a diagnostic or analytical tool in forensic science in assessing environmental and/or occupational exposures to potentially genetically toxic materials (also referred to as potential mutagens); in biotechnology, particularly in the study of the relationship between the amino acid sequence of enzymes and other biologically-active proteins or protein-containing substances and their respective functions; and in determining the effects of drugs, cosmetics and other chemicals for which toxicity data must be obtained.

Uses of the Present Method

The method of the subject invention can be utilized to determine a mutational spectrum for an individual who has been exposed to chemicals or other conditions suspected of being mutagenic. Such determinations provide information on specific effects of carcinogens. For example, if it is suspected that exposure to a genetically toxic material is the cause of a liver tumor in an individual, it is possible, using the present method, to identify the mutation(s) present in the

-19-

establish the mutational spectrum for that individual and to compare the spectrum with an appropriate reference to determine the relationship between the exposure and the resulting abnormality.

05 It is necessary, in an instance such as this, to know the history of effects (typical effects) of the genetically toxic material(s) on liver cells (e.g., a pre-established mutational spectrum) or to grow

10 normal liver cells from the individual in the presence of the material(s) and determine the resulting mutational spectrum. Comparison with either reference makes it possible to determine the extent of similarity between the reference and the spectrum of the abnormal liver cells from the

15 individual.

It is also possible to determine the mutational spectrum for T cells from an individual having a liver tumor suspected to have been caused by exposure to one or more genetically toxic materials,

20 rather than analyzing liver cells.

In either case, comparison of the spectrum determined for the individual with an appropriate reference will show whether the suspected toxic material did or did not cause a significant number

25 of mutations. A lack of similarities between the two is a clear indication that the suspected material(s) were not causative agents. Consistent presence of a particular spectrum with consistent occurrence or causation of a particular abnormality

30 (e.g., a liver tumor) provides the basis for concluding that the material is a causative agent. The extent to which DNA analysis must be carried out

-20-

well-established spectrum unique to cells exposed to a particular substance, analysis of the corresponding DNA fragment in an individual suspected of being exposed to that substance will
05 provide valuable information on which to assess exposure and its effects. In those cases in which there is no well-established and/or characteristic spectrum, the method of the present invention is
10 used to assess, for example, tumor cells and determine the mutational spectrum; to establish or determine the effects of the suspected toxic material on normal cells (e.g., by exposing and
15 growing normal cells to the material and assessing the mutational spectrum) and; to compare the two to determine causation.

The method of the present invention can be used as a diagnostic tool in forensic; environmental and occupational/occupational health contexts. For
20 example, it can be used to establish the relationship, if any, between exposure to a potentially genetically toxic substance (e.g., in community drinking water or soil, in the workplace, in urban air) and the presence of an abnormality
(e.g., tumors, blood dysphagias, etc.) The present
25 method is also useful in testing of chemicals, such as drugs, cosmetics, food additives and pesticides, before they are approved for use by consumers. For example, animals such as rats, mice and rabbits, can be exposed to a new product, such as a food
30 additive, and their DNA analyzed, by the present method, for mutations. The present method can further be used in the area of biotechnology, such

-21-

acid sequence and function of enzymes and other biologically active proteins or protein-containing materials.

05 Another useful aspect of the present invention
pertains to the identification of mutations, present
within a first mutational spectrum, which result in
a selective advantage or disadvantage for cells in
which the mutation is present. The identification
of such mutations requires mutagenesis of a cell
10 population, followed shortly thereafter by the
determination of a first mutational spectrum. The
cell population is then expanded by multiple
generation growths, followed by a determination of a
second mutational spectrum. By comparing the first
15 mutational spectrum with the second mutational
spectrum, individual mutations can be identified
whose frequency has increased, or decreased, fol-
lowing multiple generation growths.

20 A requirement of this method for detecting
mutations which confer a selective advantage or
disadvantage on cells in which they occur, is that
the cell population must be suitable for growth in
culture. Examples of such cells include mammalian
cells which can be grown in culture (e.g., HeLa...),
25 other eukaryotic cells which can be maintained in
culture (e.g., yeast...), and prokaryotic cells
(e.g., bacteria).

A variety of mutagens, well known to those
skilled in the art, can be used to introduce muta-
30 tions into DNA. Such mutagens can be introduced
into culture medium in an effective amount and
duration. Alternatively, purified DNA can be

-22-

of a suitable cell population. Methods for transformation of eukaryotic and prokaryotic cells are also well known to those skilled in the art.

05 It is important that the cell population
containing mutations be divided into two statis-
tically identical pools, a first pool and a second
pool. Shortly after treatment of a cell population
with a mutagen, or transformation of a cell popu-
lation with mutagenized DNA, a first mutational
10 spectrum is determined using the method discussed
above. DNA for the first mutational spectrum is
isolated from the first pool of cells. The second
pool of cells is expanded by multiple generation
growths. During this period of clonal expansion,
15 cells which contain a mutation conferring a selec-
tive advantage will grow more quickly than cells not
containing such a mutation. Consequently, after
expansion by multiple generation growths, the
percentage of this species of cell in the population
20 of cells will increase. Such an increase will be
reflected by a relative increase in the mutant
heteroduplex band intensity of the second mutational
spectrum autoradiograms, as compared to the mutant
heteroduplex band intensity of the first mutational
25 spectrum autoradiograms (assuming that other factors
remain constant).

In the converse situation, mutations resulting
in a selective disadvantage will be reflected by a
relative decrease in the intensity of the mutant
30 heteroduplex band in the autoradiogram of the second
mutational spectrum when compared to the autoradio-
gram of the first mutational spectrum (again,

-23-

In some cases, individual mutations may be lethal in a particular cell type. Such lethal mutations are detectable by the methods of the present invention provided that the mutations are
05 detectable in the first mutational spectrum. Because the first mutational spectrum is determined shortly after mutagenesis, a lethal mutation generally will not have had sufficient time to exert its biological effect (i.e., cell death). Such
10 mutations, therefore, will be represented in the first mutational spectrum. However, following expansion by multiple generation growths, lethal mutations, if present, will result in cell death. In such a case, the autoradiographs of the second
15 mutation spectrum will show no detectable band corresponding to the heteroduplex bands containing a lethal mutation present and detectable in the autoradiographs of the first mutational spectrum.

In another aspect, the present invention
20 pertains to the identification of conditional mutations, present within a first mutational spectrum, which result in a selective advantage or disadvantage for cells in which the mutation is present, under restrictive environmental conditions.
25 The term "conditional mutation", as used herein, refers to a mutation which confers no selective advantage or disadvantage upon cells containing the mutation under certain environmental conditions (termed permissive conditions) but does confer such
30 a selective advantage or disadvantage under certain other environmental conditions (termed restrictive conditions). This aspect of the invention is useful

-24-

for identifying naturally occurring conditional mutations, or such mutations induced by treatment with mutagenic agents.

05 To identify conditional mutations, a first
mutational spectrum is determined. This first
mutational spectrum is determined using DNA isolated
from cells which have not been exposed to restric-
10 tive conditions. Following the determination of the
first mutational spectrum, the population of cells
is exposed to restrictive growth conditions followed
by multiple generation growths under such restric-
tive conditions.

A second mutational spectrum is then deter-
15 mined. By comparing autoradiograms from the first
and second mutational spectra, individual mutations
can be identified whose frequency has increased
(selectively advantageous mutants), decreased
(selectively disadvantageous mutants), or is un-
detectable (lethal mutants) following multiple
20 generation growths under restrictive conditions.

The skilled artisan is familiar with growth
parameters which can be altered to create restric-
25 tive or permissive conditions. Such parameters
include increased or decreased temperature, osmo-
larity, or pH. Growth in deuterium-containing media
is another parameter which can be adjusted.

The methods of this invention are also useful
for identifying functional domains within a protein
of interest which are sensitive to mutational
30 perturbation. The identification of such functional
domains can lead to rational approaches to protein
engineering. Additionally, the methods are useful

- 25 -

example, promoter mutations which result in the termination of transcription of mRNA encoding an essential cellular protein, can be identified.

05 The present invention will now be illustrated by the following Exemplification, which is not to be seen as limiting in any way.

EXEMPLIFICATION

1. MATERIALS AND METHODS

Materials

10 T4 and Taq DNA polymerases were obtained from New England Biolabs (Beverly, MA); Klenow fragment of E. coli DNA polymerase I from Bethesda Research Laboratories (Gaithersburg, MD); and modified T7 DNA polymerase (or SequenaseTM) from US Biochemicals
15 (Cleveland, OH). T7 DNA polymerase (unmodified) and 2'-deoxynucleoside-5'-triphosphates as 100 mM solutions were obtained from Pharmacia (Piscataway, NJ). The oligonucleotides (Synthetic Genetics, CA) used as primers for PCR were the following:

20 for HPRT exon 3:

primer P1: 5'-CATATATTAAATATACTCAC-3'

primer P2: 5'-TCCTGATTTTATTTCTGTAG-3'

primer P3: 5'-GACTGAACGTCTTGCTCGAG-3'

for human mitochondrial fragment (299-bp):

25 primer P4: 5'-GATACTGGCATTCTTGTAGAT-3'

primer P5: 5'-GAATTTTATGGAGAAAGGGA-3'

for human 45s rRNA fragment (135-bp):

primer P6: 5'-TAGCCGGGTCACCGGTAGGC-3'

primer P7: 5'-GGGGAGGTATATCTTTCGCT-3'

-26-

To obtain end-labeled fragments, the amplification was carried out using 5'-end-labeled primers (specific activity: 150 Ci/mmol) using [γ -P³²]ATP (7000 Ci/mmol, New England Nuclear), T4 polynucleotide kinase, and the reagents in the 5' end DNA terminus labeling system (Bethesda Research Laboratories).

Genomic DNA was isolated from exponentially growing male TK6 human lymphoblasts; (Skopek, T.R. *et al.*, Biochem. Biophys. Res. Commun. **84**:411-416 (1978)), according to the method described by Porteous, (Somat. Cell Mol. Genet. **11**:445-454 (1985)). In this study, the 184-bp exon 3 sequence of the X-linked HPRT gene was used as template because it contains naturally occurring high and low temperature melting domains of 84-bp and 100-bp, respectively (Fig. 1).

Methods

The PCR conditions used for T4 DNA polymerase (Keohavong, P. *et al.*, DNA **7**:63-70 (1988)), and for both the modified and unmodified T7 DNA polymerases (Keohavong, P. *et al.*, Gene **71**:211-216 (1988)) were similar to those described for Klenow fragment (Saiki *et al.*, Science **230**:1350-1354 (1985); (Mullis *et al.*, Meth. in Enzymol. **155**:335-350 (1987)). A 100 μ l reaction mixture contained: DNA templates (5 μ g of genomic DNA or PCR products after gel purification), 10 mM Tris (pH 8.0), 5 mM MgCl₂, 2.7 mM of each dNTP (2.15 mM for T4 DNA polymerase), 3 μ M of each primer and, for T4 DNA polymerase, 5% DMSO (vol/vol). Each amplification cycle consisted of:

-27-

template hybridization 1 min at 37° C, (3) addition of 0.5 unit of T4 DNA polymerase or 2 units of modified and unmodified T7 DNA polymerases and 2 min incubation at 37° C.

05 The conditions for experiments with Klenow fragment were exactly as described in the original method. The conditions for Taq DNA polymerase (New England Biolabs) were as follows: a 100 µl reaction mixture contained: 16.6 mM (NH₄)₂SO₄, 67 mM Tris-HCl
10 (pH 8.8 at 25° C), 6.7 mM MgCl₂, 10 mM βME, 200 µM of each of the four dNTPs and 1 µM of each primer. Each amplification cycle consisted of heating the reaction mixture at 93° C for 1 min (except 3 min
15 at 53° C for 2 min, and DNA chain synthesis at 70° C for 2 min. One µl (2.5 units) of Taq DNA polymerase was added every 10 cycles following the 2 min incubation at 53° C.

20 To maximize the separation of polymerase-induced mutant sequences from the correctly amplified sequences, the PCR products were analyzed as heteroduplex mutant: wild type sequences. 5 x 10⁴ to 5 x 10⁵ cpm of the amplified DNA were diluted in 30 µl of 400 mM NaCl, 10 mM Tris pH 7.5, 2mM EDTA,
25 boiled 5 min, and allowed to anneal at 65° C for 5 h. The DNA was recovered by ethanol precipitation and electrophoresed on a 12.5% polyacrylamide gel (bis/acryl=1/37.5) containing a linearly increasing gradient of denaturant from 15% (vol/vol) to 30%
30 (vol/vol) (100% denaturant=7M urea and 40% formamide) (Myers, R.M. et al., Methods Enzymol. 155:501-527 (1987)). The gel was run for 15h at 150V

-28-

NaOAc, 1 mM EDTA pH 8.3). The gel was then fixed in 40% methanol and 5% glycerol, dried, and autoradiographed.

05 The gel was dried without fixation with methanol. Radioactive bands were first located by autoradiography and excised through the autoradiogram superimposed on the gel. The DNA was electroeluted from the gel slices and recovered by ethanol precipitation.

10 2. RESULTS

The DNA amplification was carried out from genomic DNA using primers P1 and P2 which immediately flanked the human HPRT exon 3 sequence (Fig. 1B) and the following five DNA polymerases: T4, modified and unmodified T7, Klenow fragment of Pol I, and Taq. The efficiency of amplification of the expected-size 224-bp fragment varied according to the type of the DNA polymerase. Efficiency was estimated according to the equation:

20 $(1+Y)^N$ =fold amplification,
where Y is the efficiency per cycle and N is the number of cycles performed (Saiki, R.K. et al., Science 230:1350-1354 (1985)). Efficiencies during the first 20 cycles were estimated to be 90-93% with
25 either modified or unmodified T7 DNA polymerases, 88% with Klenow fragment and Taq DNA polymerase. T4 DNA polymerase gave an efficiency of 60%, through 30 cycles. In addition to the expected-size 224-bp fragment, unwanted sequences appeared, especially
30 when using Klenow fragment. The efficiency and

-29-

polymerase was exceptional. 30 cycles yielded more than 4×10^7 fold amplification. The high efficiency obtained with modified T7 DNA polymerase probably resulted from its highly processive activity (Tabor, S. et al., J. Biol. Chem. 262:16212-16223 (1987)); (Tabor, S. et al., Proc. Natl. Acad. Sci. USA 84:4767-4771 (1987)). This enzyme has also been used to amplify several other sequences directly from human cells including a 299-bp fragment from the mitochondrial genome (Anderson, S. et al., Nature 290:457-465 (1981)) (Fig. 2B, part 1) and a 135-bp fragment from 45s ribosomal RNA genes (Schmickel, R.D. Pediat. Res. 7:5 (1973)). Furthermore, these fragments and the 224-bp exon 3 fragment were able to be simultaneously amplified in the same reaction mixture containing the three independent pairs of primers.

The 184-bp exon 3 sequence is composed of 84-bp of high temperature melting domain and 100-bp of low temperature melting domain (Fig. 1). Base-pair substitutions and small frameshift mutations throughout the low temperature melting domain of this sequence have been shown to be separable from the wild type by DGGE when first converted into heteroduplex mutant:wild type sequences. To analyze the fidelity of DNA amplification by DGGE, the PCR products were first boiled and reannealed so that each strand of the mutant homoduplexes was hybridized to the complementary strand of the correctly amplified sequences (wild type) present in excess. In this manner, each mutant sequence was expected to

-30-

separate further from the wild type than the mutant homoduplex (Myers, R.M. et al., Cold Spring Harbor Symp. Quant. Biol. 51:275-283 (1986); Tabor, S. et al., Proc. Natl. Acad. Sci. USA 84:4767-4771 (1987)). When the exon 3 sequence was separated by DGGE after 10^6 and 10^8 fold amplification for each DNA polymerase, the wild type sequence focused at 24% of denaturant concentrations, and, in addition, a series of bands were observed in lower denaturant concentrations. After 10^8 fold amplification (Fig. 3), the number of such bands varied from three with T4 DNA polymerase to more than a dozen with Klenow fragment and Taq DNA polymerase. The individual bands each represented between 1 and 3% of the total radioactive DNA analyzed on the gel. Three distinct patterns of mutant bands appeared: (a) with T4 DNA polymerase, (b) with Taq DNA polymerase, (c) with modified or unmodified T7 DNA polymerases. The pattern produced by Klenow fragment, apart from three bands, was identical to that observed with the two T7 DNA polymerases. This suggests that both the modified and unmodified T7 DNA polymerases and also Klenow fragment generated mutations of similar kinds and positions while copying the low temperature melting domain of exon 3.

The fraction of radioactivity separated as bands by DGGE was estimated by densitometry through comparison of the intensity of the putative mutant sequences relative to that of the wild type. The densitometric scanning yielded an integral total absorbance for the wild type peak and putative mutant heteroduplex region between the wild type

-31-

such as depurination within homoduplexes were accounted by eluting radioactive DNA from a wild type peak. The DNA was boiled, annealed, and separated by DGGE. This background fraction, totaling about 4%, was subtracted from the putative heteroduplex fraction. Thus, the PCR-related mutant fraction (MF) was estimated as:

MF = (absorbance in heteroduplex region - background absorbance) (1/2) / (total absorbance). The MF at 10^6 and 10^8 fold amplification were found to be 0.25% and 1.5% for T4; 3.7% and 4.5% for modified T7; 3.8% and 4.7% for unmodified T7; 11% and 16% for Klenow fragment; and 31% and 33% for Taq DNA polymerases.

The error rate (f) for each DNA polymerase was then estimated according to the equation:

$$MF = b \times f \times d$$

where b is the number of nucleotides synthesized on both strands of the template for which mutants would be detected (2 x 100 nucleotides for the low temperature melting domain of exon 3) and d is the number of duplications (10^6 and 10^8 fold amplification represented 20 and 26 duplications, respectively). The error rates (mutations/base/duplication), f, for 10^6 and 10^8 fold amplification were found to be 0.6 and 3 ($\times 10^{-6}$) for T4; 9.0 and 8.5 ($\times 10^{-6}$) for modified T7; 9.5 and 9.0 ($\times 10^{-6}$) for unmodified T7; 3 ($\times 10^{-5}$) for Klenow fragment; and 7.5 and 6.5 ($\times 10^{-5}$) for Taq DNA polymerases.

Each individual band isolated from denaturing gradient gels was amplified an additional 10^2 to 10^3 fold and separated by another DGGE. In the case of

-32-

this process resulted in two major homoduplexes, mutant and wild type. After boiling and annealing, these same DNA gave rise to two additional bands, expected to correspond to the mutant:wild type heteroduplexes. The fact that both bands gave rise to precisely the same pattern of bands after boiling and annealing was consistent with the interpretation that they were heteroduplexes formed from the opposite strands of the same mutant homoduplex.

05 Sequence analysis of these mutant homoduplexes showed a G-C to A-T substitution at position 351 (see Table 1). Two less intense bands created by T4 DNA polymerase and 14 of the most intense bands created by Taq DNA polymerase were isolated and

10 sequenced in the same manner. Some of these sequences did not yield homoduplexes sufficiently separated from the wild type by DGGE for isolation and, in this case, sequencing was carried out using the heteroduplexes. The kinds and positions of the

15 most frequent mutations found for T4 and Taq DNA polymerases are summarized in Table 1. All of the mutations determined were found to be base-pair substitutions. The three mutations induced by T4 DNA polymerase were G-C to A-T transitions. Seven

20 mutations appearing with Taq DNA polymerase were found to be A-T to G-C transitions. No additions or deletions were detected among the mutations determined. These data showed that T4 and Taq DNA polymerases catalyzed the PCR differently with

25 regard to the kinds of mutations induced in the low temperature melting domain of exon 3. T4 DNA polymerase induced a single "hot spot" G-C to A-T

30

- 33 -

seven different A-T to G-C transitions among the 32
A-T base-pairs in the low temperature melting domain
of exon 3.

-34-

Table 1. Mutations generated by T4 and Taq DNA polymerases

DNA polymerases	kinds of mutations	bands number	*positions
T4	G-C to A-T	1	319
		2	320
05		3 and 4	351
Taq	A-T to G-C	5	337
		6	399
		7	334
		8	333
10		9	371
		10	358
		11	393

* the positions of the mutations in the low temperature melting domain of exon 3 were numbered starting from the 5' end of the human HPRT cDNA (Patel et al., Somat. Cell. Mol. Genet. 10:483-493 (1984)).

-35-

The background of the polymerase-induced mutations is a limiting factor for detecting pre-existing mutants present as a small number of copies in cell populations. In order to probe this limit, 05 HPRT exon 3 was amplified using modified T7 DNA polymerase from samples of HPRT wild type cells (Skopek, T.R. et al., Biochem. Biophys. Res. Commun. 84:411-416 (1978)); containing known fractions of exon 3 mutant cells, HPRT-Munich (Cariello, N.F. et 10 al., Am. J. Hum. Genet. 42:726-734 (1988)). Analysis by DGGE showed that a mutant fraction of 10^{-3} can be detected. To further increase the sensitivity of the protocol, the heteroduplex region between the wild type band and the origin of the gel 15 was excised, the DNA was isolated and amplified an additional 10^2 fold. After separation by a second DGGE, one of the wild type:HPRT-Munich heteroduplexes present at a mutant fraction of 10^{-4} was observed. By comparison with this heteroduplex 20 band, the most prominent mutant sequences induced by modified T7 DNA polymerase corresponded to mutant fractions of about 2×10^{-4} .

- 36 -

CLAIMS

1. A method of resolving mutant DNA from non-mutant DNA, comprising the steps of:
 - 05 a) providing fragmented double-stranded DNA which is a mixture of mutant DNA-containing fragments and nonmutant DNA-containing fragments;
 - b) 10 denaturing and annealing the fragmented DNA under conditions appropriate for heteroduplex formation;
 - c) separating heteroduplexes from homoduplex molecules by denaturing gradient gel electrophoresis, and isolating the heteroduplexes;
 - 15 d) amplifying the isolated heteroduplexes by high fidelity amplification; and
 - e) 20 repeating steps (b), (c) and (d) as needed to produce for each heteroduplex a band with a characteristic location on the denaturing gradient gel.
2. A method of Claim 1 wherein the fragmented DNA is provided by treating genomic DNA isolated from cells with at least one restriction endonuclease under conditions appropriate for 25 endonuclease activity.
3. A method of Claim 2 wherein the mixture of mutant DNA-containing fragments and nonmutant DNA-containing fragments is separated on the basis of molecular weight and fragments of

- 37 -

4. A method for detecting resolution of at least one species of mutant DNA from non-mutant DNA present in a cell population, comprising the steps of:
- 05 a) isolating DNA from the population of cells;
 - b) digesting the isolated DNA with one or more appropriately-selected restriction endonucleases, to produce a mixture of DNA
 - 10 fragments;
 - c) separating the mixture of DNA fragments on the basis of molecular weight, and isolating fragments of appropriate predetermined molecular weight;
 - 15 d) denaturing and annealing the isolated fragments in the presence of an excess of nonmutant-containing homoduplex DNA, under conditions appropriate for heteroduplex formation;
 - 20 e) separating mutant-containing heteroduplexes from nonmutant-containing homoduplexes by denaturing gradient gel electrophoresis and isolating the heteroduplex fraction;
 - 25 f) amplifying the mutant-containing heteroduplexes by high fidelity amplification;
 - g) adding an excess of nonmutant-containing homoduplexes, denaturing and annealing the product of (f) in the presence of an
 - 30 excess of nonmutant-containing homoduplex DNA, under conditions appropriate for heteroduplex formation; and

-38-

- h) detectably separating mutant-containing heteroduplexes from homoduplexes by denaturing gradient gel electrophoresis.
5. A method of Claim 4 wherein the mutant DNA
05 sequence is present at a mutational frequency of from 1 to about 1×10^{-8} .
6. A method of Claim 5 wherein the cell population is a human cell population.
7. A method for determining a mutational spectrum
10 in a DNA sequence of interest present in a population of cells comprising the steps of:
- a) providing fragmented double-stranded DNA which is a mixture of mutant DNA containing fragments and nonmutant DNA containing fragments;
15
 - b) denaturing and annealing the fragmented DNA under conditions appropriate for heteroduplex formation;
 - c) separating heteroduplexes from homoduplex molecules by denaturing gradient gel electrophoresis, and isolating the hetero-
20 duplexes;
 - d) amplifying the isolated heteroduplexes by high fidelity amplification;
 - 25 e) repeating steps (b), (c) and (d) as needed to produce for each heteroduplex a band with a characteristic location on the denaturing gradient gel;

-39-

- 05 f) amplifying separately DNA in each band
produced in step (e), by high fidelity
amplification;
- g) determining the nucleotide sequence of DNA
from each band after amplification in step
(f); and
- 10 h) comparing the nucleotide sequence of each
band with the nucleotide sequence of
corresponding nonmutant DNA to determine
the difference in each.
8. A method of Claim 7 wherein the mutant DNA
sequence is present at a mutational frequency
of from 1 to about 1×10^{-8} .
- 15 9. A method of Claim 8 wherein the cell population
is a human cell population.
10. A method for determining a mutational spectrum
in a population of cells from an individual
exposed to a suspected mutagen comprising the
steps of:
- 20 a) isolating DNA from the population of
cells;
- b) digesting the isolated DNA with one or
more appropriately-selected restriction
endonucleases, to produce a mixture of DNA
25 fragments;
- c) separating the mixture of DNA fragments on
the basis of molecular weight, and iso-
lating fragments of appropriate
predetermined molecular weight;

-40-

- 05 d) denaturing and annealing the isolated fragments in the presence of an excess of nonmutant-containing homoduplex DNA, under conditions appropriate for heteroduplex formation;
- 10 e) separating mutant-containing heteroduplexes from nonmutant-containing homoduplexes by denaturing gradient gel electrophoresis and isolating the heteroduplex fraction;
- 15 f) amplifying the mutant-containing heteroduplexes by high fidelity amplification;
- g) denaturing and annealing the product of (f) in the presence of an excess of nonmutant-containing homoduplex DNA, under conditions appropriate for heteroduplex formation;
- 20 h) detectably separating mutant-containing heteroduplexes from nonmutant-containing homoduplexes by denaturing gradient gel electrophoresis to produce for each heteroduplex a band with a characteristic location on the denaturing gradient gel;
- 25 i) determining the nucleotide sequence of DNA from each band formed in step (h); and
- j) comparing the nucleotide sequence of each band with the nucleotide sequence of corresponding nonmutant DNA to determine the mutations in each.

30 11. A method for identifying a mutation which results in a selective disadvantage for


-41-



- 05 a) determining a first mutational spectrum of
a cell population shortly after exposure
to a mutagen;
- b) expanding the cell population by multiple
generation growths;
- c) determining a second mutational spectrum
of the cell population after multiple
generation growths; and
- 10 d) comparing the first mutational spectrum
with the second mutational spectrum to
identify individual mutations whose
frequency is lower in the second
mutational spectrum than in the first
mutational spectrum.
- 15 12. A method of Claim 11 wherein the mutation is
lethal.
13. A method of Claim 11 wherein the mutations are
conditional mutations and the first mutational
spectrum is compared with the second mutational
20 spectrum to determine individual mutations
whose frequency is lower following multiple
generation growths under selected restrictive
conditions.
14. The method of Claim 13 wherein the restrictive
25 condition is selected from the group consisting
of increased temperature, decreased tempera-
ture, increased pH, decreased pH, increased
osmolarity, decreased osmolarity, and the
presence of deuterium.

-42-

15. A method of identifying a mutation which results in a selective advantage for cells in which the mutation is present, comprising the steps of:
- 05 a) determining a first mutational spectrum of a cell population shortly after exposure to a mutagen;
 - b) expanding the cell population by multiple generation growths;
 - 10 c) determining a second mutational spectrum of the cell population after multiple generation growths; and
 - d) 15 comparing the first mutational spectrum with the second mutational spectrum to identify individual mutations whose frequency has increased following multiple generation growths.
16. A method of Claim 15 wherein the mutations are conditional mutations and the first mutational spectrum is compared with the second mutational spectrum to determine individual mutations whose frequency has increased following multiple generation growths under restrictive conditions.
- 20 17. The method of Claim 16 wherein the restrictive condition is selected from the group comprising: increased temperature, decreased temperature, increased pH, decreased pH, increased osmolarity, decreased osmolarity, and the presence of deuterium.
- 25 30


1/2.

Fig. 1

*Fig. 2A**Fig. 2B*

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/03932

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁵ : C 12 Q 1/68		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	C 12 Q	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	American Journal of Human Genetics, vol. 42, 1988, The American Society of Human Genetics, (Chicago, US), N.F. Cariello et al.: "Resolution of a missense mutant in human genomic DNA by denaturing gradient gel electrophoresis and direct sequencing using in vitro DNA amplification: HPRTMunich", pages 726-734 see abstract; introduction cited in the application	1, 4, 7, 10, 11, 15
Y	Proc. Nat. Acad. Sci. USA, vol. 72, no. 3, March 1975, (Washington, US), T.E. Shenk et al.: "Biochemical method for mapping mutational alterations in DNA with S1 nuclease: The location of deletions and temperature-sensitive mutations in simian virus 40", pages 989-993 see abstract; page 989, column 2, penultimate line - page 990, column 1, line 6	1, 4, 7, 10, 11, 15
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
22nd October 1990	08. 11. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	M. A. KUJER 	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	Nature, vol. 313, 7 February 1985, (London, GB), R.M. Myers et al.: "Detection of single base substitutions in total genomic DNA", pages 495-498 see the whole article --	1,4,7,10,11, 15
A	Mechanisms of DNA damage and repair: implications for carcinogenesis and risk assessment", SIMIC M.Q. et al. editors, 1986, Plenum, (New York, US), N.F. Cariello et al.: "Use of gradient denaturing gels to determine mutational spectrum in human cells", pages 439-452 see abstract; page 446, line 5 - page 448, line 6; page 449, line 32 - page 452, line 4 --	7,10
P,A	Proc. Nat. Acad. Sci. USA, vol. 86, December 1989, P. Keohavong et al.: "Fidelity of DNA polymerases in DNA amplification", pages 9253-9257 see abstract; "Materials and Methods", page 9253, column 1 - page 9254, column 1 -----	1